The Development of a Standardized Ki-67 Assay
Rodrigo Goncalves, MD, postdoctoral fellow, Washington University School of Medicine, discusses the development of a standardized Ki-67 assay.
Clinical Pearls
Rodrigo Goncalves, MD, postdoctoral fellow, Washington University School of Medicine, discusses the development of a standardized Ki-67 assay.
- Ki-67 assays are cheaper than molecular tests
- Measuring Ki-67 before treatment and 4-6 weeks into treatment can determine whether or not therapy is working
- In this trial, researchers stained slides in a standardized way and used computer software to analyze them
- Ki-67 measurement with the software was reproducible, though researchers were able to measure Ki-67 in the traditional way if needed
- Further trials are needed to verify this information
<<<
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More
